On December 20, 2017, Oxford Immunotec Ltd. (“OI Ltd.”), a wholly owned subsidiary of Oxford Immunotec Global PLC (the “Registrant”), entered into a Third Amendment to Distributorship Agreement (the “Amendment”) with Fosun Long March Medical Science Co. Ltd. and Shanghai Xin Chang Medical Device Co. Ltd. (collectively the “Distributors”). The Amendment amends the Distributorship Agreement between the parties dated October 8, 2013, as amended on April 22, 2015 and November 3, 2016, to which the Distributors purchase T-SPOT^®.TB test kits from OI Ltd. for distribution in China (the “Agreement”). The Agreement was originally filed as Exhibit 10.24 of our Registration Statement on Form S-1 (File No. 333-191737) on October 15, 2013, as Exhibit 10.1 of our Quarterly Report on Form 10Q on August 4, 2015, and as Exhibit 10.20 of our Annual Report on Form 10K on March 1, 2017. Under the Amendment, if the Distributors purchase a defined minimum quantity of T-SPOT.TB test kits by a certain date in 2017, OI Ltd. will issue a rebate equal to a certain percentage of the aggregate value of T-SPOT.TB test kits purchased by the Distributors during 2017.

The foregoing description of the Agreement does not purport to be complete and is subject to, and is qualified in its entirety by reference to the full and complete terms of the Agreement, which are incorporated by reference herein. In addition, the foregoing description of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full and complete terms of the Amendment, which will be filed as an exhibit to the Registrant’s next periodic report.

About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.